نتائج البحث - "Scartozzi, Mario"

1

Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?

المساهمون: Lai, Eleonora, Astara, Giorgio, Ziranu, Pina, Pretta, Andrea, Migliari, Marco, Dubois, Marco, Donisi, Clelia, Mariani, Stefano, Liscia, Nicole, Impera, Valentino, Persano, Mara, Tolu, Simona, Balconi, Francesca, Pinna, Giovanna, Spanu, Dario, Pireddu, Annagrazia, Saba, Giorgio, Camera, Silvia, Musio, Francesca, Puzzoni, Marco, Pusceddu, Valeria, Madeddu, Clelia, Casadei Gardini, Andrea, Scartozzi, Mario

المصدر: Critical reviews in oncology/hematology. 157

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7dc7db0bb7d2d184e729db5325bc0d7Test
https://pubmed.ncbi.nlm.nih.gov/33271389Test

2

Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?

المؤلفون: Matteo Canale, Giorgia Marisi, Giovanni Luca Frassineti, Giorgio Ercolani, Paola Ulivi, Mario Scartozzi, Francesco Giuseppe Foschi, Martina Valgiusti, Andrea Casadei Gardini, Leonardo Solaini, Alessandro Cucchetti, Serena De Matteis, Giuseppe Cabibbo

المساهمون: Marisi, Giorgia, Cucchetti, Alessandro, Ulivi, Paola, Canale, Matteo, Cabibbo, Giuseppe, Solaini, Leonardo, Foschi, Francesco G, De Matteis, Serena, Ercolani, Giorgio, Valgiusti, Martina, Frassineti, Giovanni L, Scartozzi, Mario, Gardini, Andrea Casadei, Marisi G, Cucchetti A, Ulivi P, Canale M, Cabibbo G, Solaini L, Foschi FG, De Matteis S, Ercolani G, Valgiusti M, Frassineti GL, Scartozzi M, Casadei Gardini A.

مصطلحات موضوعية: Oncology, Hepatocellular carcinoma, law.invention, Leukocyte Count, 0302 clinical medicine, Randomized controlled trial, Neutrophil-tolymphocyte ratio, law, Medicine, Neutrophil-to-lymphocyte ratio, Liver Neoplasms, Gastroenterology, MicroRNA, General Medicine, Sorafenib, Prognosis, Treatment Outcome, Liver, 030220 oncology & carcinogenesis, Biomarker (medicine), 030211 gastroenterology & hepatology, Adverse events, Angiopoietin, Biomarker, Polymorphisms, Vascular endothelial growth factor, medicine.drug, Adverse event, medicine.medical_specialty, Carcinoma, Hepatocellular, Antineoplastic Agents, Single-nucleotide polymorphism, 03 medical and health sciences, Internal medicine, Biomarkers, Tumor, Humans, Neoplasm Invasiveness, Polymorphism, Neutrophil to lymphocyte ratio, Adverse effect, business.industry, medicine.disease, digestive system diseases, Clinical Trials, Phase III as Topic, Drug Resistance, Neoplasm, Etiology, business

وصف الملف: ELETTRONICO

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b826e9eb0c546c6478852edf43a136eTest
https://www.f6publishing.com/forms/main/DownLoadFile.aspx?Type=Digital&TypeId=1&id=10.3748/wjg.v24.i36.4152&FilePath=6653979EA8CF7C72CEE02872627E422742AF58D79EA73B77DFE92CAD4070526B46A313A3A2535AE64AEE5AE4F53AC60CD045D3DA93B5FDF9Test

3

Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma

المؤلفون: Serena De Matteis, Giovanni Luca Frassineti, Gabriele Donati, Giorgio Ercolani, Andrea Casadei Gardini, Emiliano Tamburini, Giorgia Marisi, Matteo Canale, Alessandro Passardi, Paola Ulivi, Martina Valgiusti, Luca Faloppi, Mario Scartozzi, Francesco Giuseppe Foschi, Emanuela Scarpi

المساهمون: Canale, Matteo, Ulivi, Paola, Foschi, Francesco Giuseppe, Scarpi, Emanuela, De Matteis, Serena, Donati, Gabriele, Ercolani, Giorgio, Scartozzi, Mario, Faloppi, Luca, Passardi, Alessandro, Tamburini, Emiliano, Valgiusti, Martina, Marisi, Giorgia, Frassineti, Giovanni Luca, Casadei Gardini, Andrea

المصدر: Critical reviews in oncology/hematology. 129

مصطلحات موضوعية: Oncology, PD-L1, medicine.medical_specialty, Cirrhosis, Carcinoma, Hepatocellular, Radiofrequency ablation, Hepatocellular carcinoma, Alpha-fetoprotein, Circulating miRNAs, Clinical outcome, Immunotherapy, microRNAs, Nivolumab, Tremelimumab, Hematology, law.invention, 03 medical and health sciences, 0302 clinical medicine, law, Internal medicine, medicine, Circulating miRNA, Humans, Survival rate, microRNA, business.industry, Liver Neoplasms, Biomarker, medicine.disease, digestive system diseases, Survival Rate, surgical procedures, operative, Treatment Outcome, Tumor progression, Liver Neoplasm, 030220 oncology & carcinogenesis, Catheter Ablation, 030211 gastroenterology & hepatology, Liver function, Neoplasm Recurrence, Local, business, Biomarkers, Human

وصف الملف: ELETTRONICO

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe28ce84b33673a30341a2e4485f30daTest
https://pubmed.ncbi.nlm.nih.gov/30097237Test

4

Pharmacogenomics of cetuximab in metastatic colorectal carcinoma

المؤلفون: Fotious Loupakis, Vito Lorusso, Daniele Santini, Emanuela Dell'Aquila, Bruno Vincenzi, Riccardo Giampieri, Stefano Cascinu, Giuseppe Tonini, Anna Elisabetta Brunetti, Alfredo Falcone, Nicola Silvestris, Antonio Russo, Mario Scartozzi

المساهمون: Silvestris, Nicola, Vincenzi, Bruno, Brunetti, Anna Elisabetta, Loupakis, Fotiou, Dell'Aquila, Emanuela, Russo, Antonio, Scartozzi, Mario, Giampieri, Riccardo, Cascinu, Stefano, Lorusso, Vito, Tonini, Giuseppe, Falcone, Alfredo, Santini, Daniele, Silvestris, N., Vincenzi, B., Brunetti, A. E., Loupakis, F., Dell'Aquila, E., Russo, A., Scartozzi, M., Giampieri, R., Cascinu, S., Lorusso, V., Tonini, G., Falcone, A., Santini, D.

المصدر: Pharmacogenomics. 15:1701-1715

مصطلحات موضوعية: Oncology, Settore MED/06 - Oncologia Medica, Cost effectiveness, Colorectal cancer, cost-effectivene, Cetuximab, Colorectal Neoplasm, Pharmacology, Antineoplastic Agent, Phosphatidylinositol 3-Kinases, Mutational status, Medicine, Neoplasm Metastasis, cetxuximab, Proto-Oncogene Protein, TOR Serine-Threonine Kinase, Pharmacogenetic, TOR Serine-Threonine Kinases, Neoplasm Metastasi, ErbB Receptors, Molecular Medicine, Colorectal Neoplasms, Human, medicine.drug, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, pharmacogenomic, EGFR, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, resistance, Proto-Oncogene Proteins p21(ras), Genetic, colorectal carcinoma, Proto-Oncogene Proteins, Internal medicine, Genetics, Humans, predictive, cost-effectiveness, neoplasms, pharmacogenomics, business.industry, PTEN Phosphohydrolase, ras Protein, medicine.disease, digestive system diseases, Drug Resistance, Neoplasm, Pharmacogenetics, Pharmacogenomics, Mutation, ras Proteins, Receptor, Epidermal Growth Factor, Phosphatidylinositol 3-Kinase, business, Proto-Oncogene Proteins c-akt, RAS

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97d6d84caab4f75b58e917247238b6b9Test
https://doi.org/10.2217/pgs.14.124Test

5

Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients

المساهمون: Cascinu, Stefano, Rosati, Gerardo, Bilancia, Domenico, Nasti, Guglielmo, Iaffaioli, Rosario Vincenzo, Lonardi, Sara, Zagonel, Vittorina, Zaniboni, Alberto, Marchetti, Paolo, Romiti, Adriana, Leone, Francesco, Aglietta, Massimo, Giordano, Monica, Corsi, Domenico C., Ferraú, Francesco, Labianca, Roberto, Mosconi, Stefania, Ronzoni, Monica, Gianni, Luca, Rulli, Eliana, Poli, Davide, Galli, Francesca, Torri, Valter, De Simone, Irene, Galli, Fabio, Pasini, Felice, Rangoni, Giovanni, Venezia, Raffaele, Sozzi, Pietro, Nuzzo, Antonio, Berardi, Rossana, Frontini, Luciano, Rota, Silvia, Cozzi, Lorena, Scartozzi, Mario

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Organoplatinum Compounds, Colorectal cancer, Antibodie, Leucovorin, Cetuximab, Colorectal Neoplasm, Kaplan-Meier Estimate, 0302 clinical medicine, FOLFOX, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Humanized, Metastatic colorectal cancer, Hazard ratio, Middle Aged, Oxaliplatin, Bevacizumab, Fluorouracil, 030220 oncology & carcinogenesis, FOLFIRI, Female, Colorectal Neoplasms, medicine.drug, Human, medicine.medical_specialty, Treatment sequence, Antibodies, Monoclonal, Humanized, Irinotecan, K-RAS wild type, Treatment strategy, Aged, Camptothecin, Carcinoma, Disease-Free Survival, Humans, Antibodies, 03 medical and health sciences, Internal medicine, medicine, Antineoplastic Combined Chemotherapy Protocol, business.industry, Organoplatinum Compound, medicine.disease, digestive system diseases, 030104 developmental biology, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63d7c8c030e9cd0f7d209e2de80fc74eTest
http://www.journals.elsevier.com/european-journal-of-cancerTest/

6

Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib. Validation study and biological rationale

المساهمون: Casadei Gardini, Andrea, Faloppi, Luca, De Matteis, Serena, Foschi, Francesco Giuseppe, Silvestris, Nicola, Tovoli, Francesco, Palmieri, Vincenzo, Marisi, Giorgia, Brunetti, Oronzo, Vespasiani-Gentilucci, Umberto, Perrone, Giuseppe, Valgiusti, Martina, Granato, Anna Maria, Ercolani, Giorgio, Negrini, Giulia, Tamburini, Emiliano, Aprile, Giuseppe, Passardi, Alessandro, Santini, Daniele, Cascinu, Stefano, Frassineti, Giovanni Luca, Scartozzi, Mario

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Time Factors, Type II diabetes mellitus, Databases, Factual, Hepatocellular carcinoma, medicine.medical_treatment, Kaplan-Meier Estimate, Antineoplastic Agent, 0302 clinical medicine, Retrospective Studie, Sirtuin 3, Insulin, Drug Interactions, Aged, 80 and over, Clinical pathology, SIRT-3, Liver Neoplasms, NASH, hepatocellular carcinoma, Sorafenib, Middle Aged, Immunohistochemistry, Metformin, Treatment Outcome, Drug Interaction, Italy, Liver Neoplasm, 030220 oncology & carcinogenesis, Female, Liver cancer, medicine.drug, Human, Phenylurea Compound, Adult, Niacinamide, medicine.medical_specialty, Carcinoma, Hepatocellular, Time Factor, Type II diabetes mellitu, Protein Kinase Inhibitor, Antineoplastic Agents, Disease-Free Survival, 03 medical and health sciences, Internal medicine, NAFLD, medicine, Humans, Hypoglycemic Agents, In patient, neoplasms, Protein Kinase Inhibitors, Aged, Retrospective Studies, Hypoglycemic Agent, business.industry, Phenylurea Compounds, sorafenib, metformin, medicine.disease, digestive system diseases, 030104 developmental biology, Diabetes Mellitus, Type 2, Drug Resistance, Neoplasm, business

وصف الملف: ELETTRONICO

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::853236aa38fd8b4cdee6d0527852c888Test
https://hdl.handle.net/11573/1642204Test

7

Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib

المؤلفون: Luca Faloppi, Nicola Silvestris, Giorgio de Stefano, Daniele Santini, Giorgio Ercolani, Francesco Giuseppe Foschi, Francesca Negri, Mario Scartozzi, Emanuela Scarpi, Giorgia Marisi, Giovanni Luca Frassineti, Andrea Casadei Gardini, Martina Valgiusti

المساهمون: Gardini, Andrea Casadei, Scarpi, Emanuela, Faloppi, Luca, Scartozzi, Mario, Silvestris, Nicola, Santini, Daniele, de Stefano, Giorgio, Marisi, Giorgia, Negri, Francesca V., Foschi, Francesco Giuseppe, Valgiusti, Martina, Ercolani, Giorgio, Frassineti, Giovanni Luca, Casadei Gardini, Andrea, Negri, Francesca V

المصدر: Europe PubMed Central
Oncotarget

مصطلحات موضوعية: Male, 0301 basic medicine, Hepatocellular carcinoma, Kaplan-Meier Estimate, 0302 clinical medicine, systemic immune-inflammation index, Biomarker, Inflammation, Neutrophil-to-lymphocyte ratio, Systemic immune-inflammation index, Oncology, Liver Neoplasms, hepatocellular carcinoma, Middle Aged, Sorafenib, Prognosis, University hospital, 030220 oncology & carcinogenesis, biomarker, Female, Research Paper, medicine.drug, Immune inflammation, Adult, Niacinamide, medicine.medical_specialty, Carcinoma, Hepatocellular, Antineoplastic Agents, Disease-Free Survival, 03 medical and health sciences, neutrophil-to-lymphocyte ratio, Internal medicine, Biomarkers, Tumor, medicine, Humans, In patient, Neutrophil to lymphocyte ratio, neoplasms, Aged, Proportional Hazards Models, Retrospective Studies, Interventional Ultrasound, business.industry, Phenylurea Compounds, fungi, Immune modulation, medicine.disease, digestive system diseases, Surgery, 030104 developmental biology, inflammation, business

وصف الملف: STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e56a99ed240a03a005e5973c4c4f012Test
http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=download&pathTest[]=11565&path[]=36631

8

Efficacy of sorafenib in BRAF-mutated nonsmall- cell lung cancer (NSCLC) and no response in synchronous BRAF wild typehepatocellular carcinoma: A case report

المؤلفون: Paola Ulivi, Andrea Casadei Gardini, Giorgia Marisi, Luca Faloppi, Alessandra Dubini, Cristian Loretelli, Devil Oboldi, Elisa Chiadini, Alessandro Lucchesi, Angelo Delmonte, Giovanni Luca Frassineti, Mario Scartozzi

المساهمون: Casadei Gardini, Andrea, Chiadini, Elisa, Faloppi, Luca, Marisi, Giorgia, Delmonte, Angelo, Scartozzi, Mario, Loretelli, Cristian, Lucchesi, Alessandro, Oboldi, Devil, Dubini, Alessandra, Frassineti, Giovanni Luca, Ulivi, Paola

المصدر: BMC Cancer

مصطلحات موضوعية: 0301 basic medicine, Oncology, Sorafenib, Male, Niacinamide, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Cancer Research, Carcinoma, Hepatocellular, Lung Neoplasms, non-small cell lung cancer (NSCLC), Case Report, NSCLC, Metastasis, BRAF, Neoplasms, Multiple Primary, 03 medical and health sciences, 0302 clinical medicine, Renal cell carcinoma, Internal medicine, Carcinoma, Non-Small-Cell Lung, Case report, medicine, Genetics, Humans, HCC, Lung cancer, neoplasms, Aged, business.industry, Phenylurea Compounds, Liver Neoplasms, medicine.disease, Gemcitabine, digestive system diseases, respiratory tract diseases, 030104 developmental biology, Treatment Outcome, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Mutation, business, Progressive disease, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84ee173a7cec5a25cd0d0b3494d057e2Test
https://hdl.handle.net/11380/1177444Test

9

eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study

المساهمون: Casadei Gardini, Andrea, Marisi, Giorgia, Faloppi, Luca, Scarpi, Emanuela, Foschi, Francesco Giuseppe, Iavarone, Massimo, Lauletta, Gianfranco, Corbelli, Jody, Valgiusti, Martina, Facchetti, Floriana, della Corte, Cristina, Neri, Luca Maria, Tamberi, Stefano, Cascinu, Stefano, Scartozzi, Mario, Amadori, Dino, Nanni, Oriana, Tenti, Elena, Ulivi, Paola, Frassineti, Giovanni Luca

المصدر: Oncotarget

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Hepatocellular carcinoma, Kaplan-Meier Estimate, angiogenesis, single nucleotide polymorphisms, 0302 clinical medicine, Enos, Angiogenesis, Biomarkers, Endothelial nitric oxide synthase, Single nucleotide polymorphisms, angiogenesis, biomarkers, endothelial nitric oxide synthase, hepatocellular carcinoma, single nucleotide polymorphisms, Aged, 80 and over, Univariate analysis, biology, Liver Neoplasms, hepatocellular carcinoma, Middle Aged, Sorafenib, University hospital, Angiogenesi, 030220 oncology & carcinogenesis, Female, medicine.drug, Research Paper, Adult, Niacinamide, medicine.medical_specialty, Carcinoma, Hepatocellular, Genotype, Nitric Oxide Synthase Type III, Antineoplastic Agents, Polymorphism, Single Nucleotide, Disease-Free Survival, NO, 03 medical and health sciences, Internal medicine, medicine, Humans, neoplasms, Aged, Retrospective Studies, endothelial nitric oxide synthase, Direct sequencing, business.industry, Phenylurea Compounds, biomarkers, Retrospective cohort study, Biomarker, medicine.disease, biology.organism_classification, digestive system diseases, Surgery, Single nucleotide polymorphism, 030104 developmental biology, Drug Resistance, Neoplasm, Case-Control Studies, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbb2929fb11c8cc5a1d258ef0c0ce6d4Test
http://hdl.handle.net/11392/2344804Test

10

Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib

المؤلفون: Oriana Nanni, Francesco Giuseppe Foschi, Emanuela Scarpi, Giovanni Luca Frassineti, Oronzo Brunetti, Andrea Casadei Gardini, Giorgia Marisi, Stefano Tamberi, Mario Scartozzi, Paola Ulivi, Nicola Silvestris, Emiliano Tamburini, Caterina Vivaldi, Luca Faloppi, Gianluca Masi, Elena Tenti, Stefano Cascinu, Salvatore Ricca Rosellini

المساهمون: Casadei Gardini, Andrea, Marisi, Giorgia, Scarpi, Emanuela, Scartozzi, Mario, Faloppi, Luca, Silvestris, Nicola, Masi, Gianluca, Vivaldi, Caterina, Brunetti, Oronzo, Tamberi, Stefano, Foschi, Francesco Giuseppe, Tamburini, Emiliano, Tenti, Elena, Ricca Rosellini, Salvatore, Ulivi, Paola, Cascinu, Stefano, Nanni, Oriana, Frassineti, Giovanni Luca

مصطلحات موضوعية: Drug Resistance, Gastroenterology, Pharmacology (medical), diabetes, Liver Neoplasms, hepatocellular carcinoma, insulin, metformin, sorafenib, Antineoplastic Agents, Carcinoma, Hepatocellular, Diabetes Mellitus, Type 2, Drug Resistance, Neoplasm, Humans, Hypoglycemic Agents, Metformin, Niacinamide, Phenylurea Compounds, Protein Kinase Inhibitors, Retrospective Studies, Survival Analysis, Treatment Outcome, Pharmacology, General Medicine, Sorafenib, Hepatocellular carcinoma, Type 2, medicine.drug, medicine.medical_specialty, Internal medicine, Diabetes mellitus, Diabetes Mellitus, medicine, neoplasms, Survival analysis, business.industry, Carcinoma, Type 2 Diabetes Mellitus, Hepatocellular, Retrospective cohort study, medicine.disease, digestive system diseases, Surgery, diabete, Concomitant, Neoplasm, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad951318baaf42d0b46e55e75522fcfaTest
https://hdl.handle.net/11380/1177519Test

تنقيح النتائج